Refine by
Epitope Technology Serving Mongolia
5 companies found
Technologybased inWoburn, MASSACHUSETTS (USA)
Founded in 2007, HUABIO is dedicated to developing curated, high-quality antibodies that advance innovation. We're passionate about the accuracy, efficiency, and consistency of our products. We devote our company mission to the disruption of an ...
These antibodies are actually a collection of immunoglobulin molecules that react against a specific antigen, each identifying a different epitope on an ...
Technologybased inDaejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
Epitope is a part of an antigenic protein consisting of a sequence of 8 to 15 amino acids that provide the immunogenicity of an antigen protein. Immune receptors such as TCR, BCR, and MHC of various immune cells including T cells, B ...
Technologybased inRehovot, ISRAEL
Biolojic Design is committed to curing patients by designing and developing a pipeline of revolutionary therapeutics. Biolojic’s platform generates antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: ...
Redefining What Antibodies Can Do: Biolojic’s platform generates antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: agonism, antagonism and selective binding. The platform also ...
Technologybased inCambridge, UNITED KINGDOM
Based in Cambridge, one of Europe's largest bioscience hubs, Biorbyt has a simple yet challenging mission: to provide the best service to the global scientific community. We achieve this by collaborating with the world’s finest researchers and ...
Antibodies, also known as immunoglobulins (Ig), usually have a high affinity to a specific antigen, binding only to one epitope/binding site on an antigen. Monoclonal (Mab) or polyclonal (pAb) antibodies are used in scientific ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...